GLDN and cancer: As shown in Figure 7, we analyzed the patient sample data of other cancers (bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, etc.)in the Oncomine database and found that the expression of ANGPT2, EMCN, GLDN, USHBP1, ZNF532 gene was significantly upregulated in most tumor tissue samples compared to the adjacent normal tissue samples.